Hormonal
GLP-1 receptor agonists (GLP-1RAs) improve hepatic steatosis and reduce liver fat content in patients with Type 2 Diabetes Mellitus (T2DM) and Nonalcoholic Fatty Liver Disease (NAFLD), with some agents also demonstrating the ability to resolve NASH histology.
If you have Type 2 Diabetes and fatty liver, GLP-1 medications (like liraglutide or semaglutide) are strongly supported by evidence to reduce liver fat and improve liver inflammation. They are not yet a standalone 'liver drug' but are recommended for your diabetes, which concurrently helps your liver. Discuss these options with your doctor, especially if you have biopsy-proven NASH, as they can resolve the condition in a majority of patients treated with semaglutide.
Some representatives of this class of antihyperglycemic agents emerged as potentially beneficial in patients with NAFLD after several research studies suggested they reduce hepatic steatosis, ameliorate lesions of nonalcoholic steatohepatitis (NASH), or delay the progression of fibrosis in this population.
Why this rating
Based on a review of multiple RCTs and meta-analyses showing consistent improvements in liver enzymes and fat content, though biopsy-proven fibrosis improvement is less consistent.
Source
Glucagon-like Peptide-1 Receptor Agonists in Patients with Type 2 Diabetes Mellitus and Nonalcoholic Fatty Liver Disease—Current Background, Hopes, and Perspectives
Georgiana-Diana Cazac et al. · Metabolites · 2023
DOI 10.3390/metabo13050581
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →